TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population
Table 4
The associations between TSP-1-1223 A/G polymorphism and the development of bladder cancer.
Variables
Genotypes
Crude OR (95% CI)
Adjusted OR (95% CI)b
AA + AG
GG
%
%
Controls ()
592
88.4
78
11.6
1.00 (reference)
1.00 (reference)
Cases ()
Tumor stage
Nonmuscle invasive
407
87.3
59
12.7
0.604
1.10 (0.75–1.60)
0.341
1.21 (0.82–1.79)
Muscle invasive
125
87.4
18
12.6
0.750
1.09 (0.59–1.92)
0.488
1.23 (0.68–2.22)
Tumor grade
Grade 1
264
88.6
34
11.4
0.917
0.98 (0.62–1.52)
0.842
1.05 (0.67–1.65)
Grade 2
168
86.6
26
13.4
0.507
1.17 (0.70–1.92)
0.271
1.35 (0.79–2.30)
Grade 3
100
85.5
17
14.5
0.376
1.29 (0.69–2.31)
0.158
1.58 (0.84–2.97)
Number
Single
384
88.1
52
11.9
0.886
1.03 (0.69–1.52)
0.550
1.13 (0.76–1.69)
Multiple
148
85.5
25
14.5
0.315
1.28 (0.75–2.12)
0.160
1.47 (0.86–2.50)
Size
<3 cm
345
88.2
46
11.8
0.952
1.01 (0.67–1.51)
0.800
1.06 (0.70–1.60)
≥3 cm
187
85.8
31
14.2
0.314
1.26 (0.78–2.00)
0.074
1.56 (0.96–2.55)
CI: confidence interval; OR: odds ratio. Two-sided test for either genotype distributions or allele frequencies between the cases and controls.
bAdjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.
